Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients.
BACKGROUND
Lanthanum carbonate is a non-aluminum, non-calcium phosphate binder. Its efficacy and its safety profile up to 1 year have been reported in Japanese hemodialysis patients.


METHODS
The present study was an extension of the earlier study. One hundred and forty-five patients were enrolled in the original 1 year observational Phase III study. After 1 year of treatment, 63 patients continued with further lanthanum treatment. Lanthanum carbonate was administered at 750-4,500 mg/day for up to 156 weeks (3 years). The reduction in serum phosphate was used to evaluate efficacy, and laboratory markers of bone turnover were monitored.


RESULTS
The serum phosphate level was maintained at a significantly lower level (P < 0.05) than the baseline level during the 3-year study period. Most of the drug-related adverse events were mild and were mainly gastrointestinal disorders. The safety profile of lanthanum during 3 years of treatment was similar to that seen in the previous study. There were no clinically relevant changes in vital signs or the electrocardiogram. Bone turnover markers, such as osteocalcin, bone-specific alkaline phosphatase, and crosslinked N-telopeptide of type I collagen, showed no clinically relevant changes.


CONCLUSIONS
Lanthanum therapy was able to reduce and maintain the serum phosphate level within the K/DOQI and JSDT guideline ranges in Japanese dialysis patients for 3 years.
Shigematsu
Takashi
T
Division of Nephrology and Blood Purification Medicine, Department of Medicine, Wakayama Medical University, 881-1 Kimiidera, Wakayama, Wakayama 641-8509, Japan. taki@wakayama-med.ac.jp
D000368:Aged; D044466:Asian People; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D007811:Lanthanum / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis; D016896:Treatment Outcome; D014807:Vitamin D / Q000627:therapeutic use
D010710:Phosphates; D014807:Vitamin D; C119467:lanthanum carbonate; D007811:Lanthanum
Nephron Clin Pract. 2005;100(1):c8-19
15809508
Nephrol Dial Transplant. 2004 Jul;19(7):1902-6
15199195
Am J Kidney Dis. 1998 Apr;31(4):607-17
9531176
Nephron Clin Pract. 2006;102(2):c61-71
16224198
Nephrol Dial Transplant. 2006 Aug;21(8):2217-24
16595583
Clin Nephrol. 2004 Sep;62(3):193-201
15481851
Kidney Int. 2009 May;75(9):906-14
19279554
Clin Nephrol. 2008 Nov;70(5):404-10
19000540
Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):16-21
15486869
J Am Soc Nephrol. 2008 Jun;19(6):1092-105
18417722
Ther Apher Dial. 2008 Feb;12(1):55-61
18257813
Clin Nephrol. 2005 Dec;64(6):428-37
16370155
Ther Apher Dial. 2010 Feb;14(1):12-9
20438515
Am J Kidney Dis. 2003 Jul;42(1):96-107
12830461
Curr Med Res Opin. 2005 May;21(5):657-64
15969865
Kidney Int Suppl. 2004 Sep;(90):S8-S12
15296501
Semin Dial. 2006 May-Jun;19(3):195-9
16689967
Nephrol Dial Transplant. 2005 Apr;20(4):775-82
15703206
Clin Nephrol. 2006 Mar;65(3):191-202
16550750
Kidney Int Suppl. 2003 Jun;(85):S73-8
12753271
Clin Nephrol. 2005 Jun;63(6):461-70
15960148
Nephron Clin Pract. 2008;110(1):c15-23
18667837
Ther Clin Risk Manag. 2008 Oct;4(5):887-93
19209270
J Clin Pharmacol. 2006 Jul;46(7):738-46
16809799